Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 3/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13134027 | 0.92 | FGFR2 (0.37) | MAP2K4FGFR2FGFR3FGFR1NR1H2 | |
| SCHEMBL13282969 | 0.91 | FGFR1 (0.41) | FGFR2FGFR3FGFR1NR1H2NR1H3 | |
| SCHEMBL3551052 | 0.91 | FGFR2 (0.36) | FGFR2FGFR3FGFR1NR1H2NR1H3 | |
| SCHEMBL3544800 | 0.87 | PPARG (0.34) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL3548104 | 0.87 | PPARG (0.42) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL3540909 | 0.87 | PPARG (0.37) | MAP2K4FGFR2FGFR3FGFR1NR1H2 | |
| SCHEMBL3554183 | 0.86 | NR1H2 (0.35) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL3553672 | 0.82 | KDM4E (0.37) | — | |
| SCHEMBL5822442 | 0.82 | PPARG (0.47) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL5630819 | 0.82 | PPARG (0.47) | NR1H2NR1H3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| EP-1907381-A4 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1907381-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007008501-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008501-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | MAP2K4 1842/4885FGFR2 300/4885FGFR3 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.